The rationale and study design of two phase II trials examining the effects of BI 685509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis
| Image |  |
|---|---|
| Description | scientific article published in 2023 |
| Author/s |
author: Thomas Reiberger |
| Publication date | April 24, 2023 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |